Global Hospital-acquired Disease Testing Market 2015-2019
About Hospital-acquired Diseases
Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient.
Technavio's analysts forecast the global hospital-acquired disease testing market to grow at a CAGR of 19.44% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and the growth prospects of the global hospital-acquired disease testing market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of testing products used in the following hospital-acquired disease infections: SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and others.
Technavio's report, Global Hospital-acquired Disease Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital-acquired disease testing market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key Regions
Technavio Announces the Publication of its Research Report – Global Hospital Acquired Disease Testing Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Hospital Acquired Disease Testing Market: Abbott Laboratories Inc., Becton and Dickenson (BD), bioMerieux SA and Roche Diagnostics
Other Prominent Vendors in the market are: Akers Biosciences, Alere, Beckman Coulter/Danaher, Cantel Medical, Cepheid, Diatherix Laboratories, Eiken Chemical, Enzo Biochem, Fujirebio/Innogenetics, Gen-Probe, Humor Diagnostica, Life Technologies, Meridian Bioscience, Nordion and QIAGEN
Commenting on the report, an analyst from Technavio’s team said: “The technological advance in the molecular diagnostic field is one of the key trends in the global hospital acquired disease testing market. The continuous innovation in increasing the performance and speed of molecular diagnostics is an integral part of the infectious diagnostic testing field.”
According to the report, the rising prevalence of hospital acquired infections has a significant impact on both developed and developing countries and remains one of the major drivers of the growth of the market.
Further, the report states that lack of healthcare infrastructure, training, and awareness of how hospital acquired infections spread remain major hindrances to the growth of the market. Early diagnosis and regular monitoring of patients with these diseases is essential to identify, treat, and control their spread. This has generated substantial demand for hospital acquired disease testing products including instruments, testing kits, and reagents.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit- http://www.technavio.com/report/hospital-acquired-disease-testing-market
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook